Cargando…

Dual Erb B Inhibition in Oesophago-gastric Cancer (DEBIOC): A phase I dose escalating safety study and randomised dose expansion of AZD8931 in combination with oxaliplatin and capecitabine chemotherapy in patients with oesophagogastric adenocarcinoma

BACKGROUND: AZD8931 has equipotent activity against epidermal growth factor receptor, erbB2, and erbB3. Primary objectives were to determine the recommended phase II dose (RP2D) of AZD8931 + chemotherapy, and subsequently assess safety/preliminary clinical activity in patients with operable oesophag...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thomas, Anne, Virdee, Pradeep S., Eatock, Martin, Lord, Simon R., Falk, Stephen, Anthoney, D. Alan, Turkington, Richard C., Goff, Matthew, Elhussein, Leena, Collins, Linda, Love, Sharon, Moschandreas, Joanna, Middleton, Mark R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Science Ltd 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6947485/ https://www.ncbi.nlm.nih.gov/pubmed/31765988 http://dx.doi.org/10.1016/j.ejca.2019.10.010

Ejemplares similares

The impact of chemosensory and food-related changes in patients with advanced oesophagogastric cancer treated with capecitabine and oxaliplatin: a qualitative study
por: de Vries, Yfke C., et al.
Publicado: (2016)

ICORG 10-14: NEOadjuvant trial in Adenocarcinoma of the oEsophagus and oesophagoGastric junction International Study (Neo-AEGIS)
por: Reynolds, JV, et al.
Publicado: (2017)

Toxicity associated with capecitabine plus oxaliplatin in colorectal cancer before and after an institutional policy of capecitabine dose reduction
por: Baird, R, et al.
Publicado: (2011)

Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial
por: Waddell, Tom, et al.
Publicado: (2013)

Dose-finding study of oxaliplatin associated to capecitabine-based preoperative chemoradiotherapy in locally advanced rectal cancer
por: Bruera, Gemma, et al.
Publicado: (2018)

Combining AZD8931, a novel EGFR/HER2/HER3 signalling inhibitor, with AZD5363 limits AKT inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified breast cancer models
por: CRAFTER, CLAIRE, et al.
Publicado: (2015)

BACE1 Inhibitor MK-8931 Alters Formation but Not Stability of Dendritic Spines
por: Blume, Tanja, et al.
Publicado: (2018)

Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF
por: Sumpter, K, et al.
Publicado: (2005)

A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine
por: Twelves, Chris, et al.
Publicado: (2019)

Dose-escalated neoadjuvant chemoradiotherapy for locally advanced oesophageal or oesophagogastric junctional adenocarcinoma
por: Duque-Santana, Victor, et al.
Publicado: (2022)

A phase II study of capecitabine and oxaliplatin combination chemotherapy in patients with inoperable adenocarcinoma of the gall bladder or biliary tract
por: Graham, J. S., et al.
Publicado: (2016)

PANTHER: AZD8931, inhibitor of EGFR, ERBB2 and ERBB3 signalling, combined with FOLFIRI: a Phase I/II study to determine the importance of schedule and activity in colorectal cancer
por: Propper, David J., et al.
Publicado: (2022)

Two doses of NGR-hTNF in combination with capecitabine plus oxaliplatin in colorectal cancer patients failing standard therapies
por: Mammoliti, S., et al.
Publicado: (2011)

Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer
por: Rao, S, et al.
Publicado: (2008)

Economic comparison of capecitabine + oxaliplatin and 5-fluorouracil + oxaliplatin in the adjuvant treatment of colon cancer
por: Aitini, Enrico, et al.
Publicado: (2012)

Propofol Sedation for Oesophago-Gastro-Duodenoscopy
por: Watt, J. M., et al.
Publicado: (1999)

AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models
por: Mu, Zhaomei, et al.
Publicado: (2014)

Capecitabine, 5-fluorouracil and S-1 based regimens for previously untreated advanced oesophagogastric cancer: A network meta-analysis
por: ter Veer, Emil, et al.
Publicado: (2017)

Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis
por: Zarate, R, et al.
Publicado: (2010)

Retrospective study of preoperative chemoradiotherapy with capecitabine versus capecitabine plus oxaliplatin for locally advanced rectal cancer
por: Yang, Xiao-Hui, et al.
Publicado: (2020)

Capecitabine Plus Oxaliplatin Combination Therapy for Basal Cell Carcinoma
por: Rhee, Jiyoung, et al.
Publicado: (2019)

The pattern of recurrence of adenocarcinoma of the oesophago-gastric junction
por: Wayman, J, et al.
Publicado: (2002)

Double stenting for malignant oesophago-respiratory fistula
por: Włodarczyk, Janusz, et al.
Publicado: (2016)

Immune Checkpoint Inhibition in Oesophago-Gastric Carcinoma
por: Högner, Anica, et al.
Publicado: (2021)

Dose-intense capecitabine, oxaliplatin and bevacizumab as first line treatment for metastatic, unresectable colorectal cancer: a multi-centre phase II study
por: Jackson, Christopher GCA, et al.
Publicado: (2014)

Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial
por: Madi, A, et al.
Publicado: (2012)

Thrombosis with thrombocytopenia after second dose of AZD-1222
Publicado: (2021)

Cost-effectiveness analysis of capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer
por: Peng, Jingyuan, et al.
Publicado: (2018)

Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial
por: Tebbutt, N C, et al.
Publicado: (2010)

Low-dose capecitabine (Xeloda) for treatment for gastrointestinal cancer
por: Miger, Jasmine, et al.
Publicado: (2014)

Combination of Capecitabine and Oxaliplatin is an Effective Treatment Option for Advanced Neuroendocrine Tumors
por: Ferrarotto, Renata, et al.
Publicado: (2013)

Postoperative Chemoradiotherapy With Capecitabine and Oxaliplatin vs Capecitabine for Stage II to III Rectal Cancer: A Randomized Clinical Trial
por: Li, Ning, et al.
Publicado: (2021)

Optimising Multimodality Treatment of Resectable Oesophago-Gastric Adenocarcinoma
por: Suwaidan, Ali Abdulnabi, et al.
Publicado: (2022)

Comparison of toxicity and effectiveness between fixed-dose and body surface area-based dose capecitabine
por: de Man, Femke M., et al.
Publicado: (2019)

Neoadjuvant Capecitabine and Oxaliplatin Before Concurrent Capecitabine and Radiation in Locally Advanced Rectal Cancers: Experience of a Cancer Hospital in Pakistan
por: Mansha, Muhammad Atif, et al.
Publicado: (2021)

Cost-effectiveness of oxaliplatin and capecitabine in the adjuvant treatment of stage III colon cancer
por: Eggington, S, et al.
Publicado: (2006)

Identification of biomarkers predicting the chemotherapeutic outcomes of capecitabine and oxaliplatin in patients with gastric cancer
por: Zhang, Yan, et al.
Publicado: (2020)

mRNA profiling of the cancer degradome in oesophago–gastric adenocarcinoma
por: Baren, J P, et al.
Publicado: (2012)

The rare case of oesophago-pericardial fistula secondary to pulmonary tuberculosis
por: Sidhu, Kavina Kaur, et al.
Publicado: (2022)

A Muti-center, Randomized Phase II Study of Oxaliplatin and S-1 versus Capecitabine and Oxaliplatin in Patients with Metastatic Colorectal Cancer
por: Kim, Jung Han, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_6i8iega8o6iagi64rmrgeg73pf